Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available for PAH management. Phosphodiesterase type 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatment; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
  •  How have Uptravi, Orenitram, and Adempas been integrated into the treatment algorithm and what are their sources of business?
  •  What percentage of PAH patients receive drug therapy within two years of diagnosis, and how quickly?
  • What percentage of patients progress to later lines of therapy within two years of diagnosis?
  •  What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
  •  What are the product-level compliance and persistency rates among drug-treated PAH patients?

Geographies

United States

Real world data Longitudinal patient-level claims data analysis

Key Drugs Covered

Adcirca, Tracleer, Letairis, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, sildenafil, epoprostenol Key Analysis provided Brand/therapy usage across longitudinal patient sample Newly diagnosed patient analysis Treatment initiation and progression Line of therapy analysis Combination therapy analysis Source of business for recently treated patients Persistency and compliance analysis Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.


Related Reports

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (EU5)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread because drugs have been approved only for the...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of dr...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details